We use cookies to help us improve the website and your experience using it. You may delete and block all cookies from this site at any time. However, please note this may result in parts of the site no longer working correctly. If you continue without changing your settings we will assume you are happy to receive all cookies on this site.

Close

Acute Myeloid Leukaemia

MRD monitoring is used to guide therapy and identify those patients at an increased risk of relapse. Paired PB and BM samples are required to accurately determine levels of MRD. This is because there can be large differences in the interpretation of the relapse risk if you are looking at leukaemic gene expression in PB or BM alone.

For this reason, it is important to identify the sample type (PB or BM) on the requisition form or request card.

The accurate monitoring of MRD requires samples to be fresh, to reach us ideally within 24 hours of phlebotomy and no later than 48 hours for reliable result generation. When it is not possible to obtain both samples, it is advised to send one sample PB or BM rather than miss the time point of MRD monitoring and the interpretation of the results will take this into account.